The Trump Administration Advisor Set to Become Next FDA Lead

Awaiting Senate confirmation, Heidi Overton, MD, PhD, has been nominated to become the next leader of the FDA following the departure of Marty Makary, MD, PhD, in May as well as Brad Wenstrup and acting FDA Commissioner Kyle Diamantas, JD, turning down the role.

Overton, a known vaccine skeptic and anti-abortion advocate, according to NBC News, will be watched closely in her new position as a staunch Trump supporter with similar health care views and policies as the greater presidential administration.¹

Prior to entering the role, Overton had been a certified physician and White House policy official who regularly advises the president. She was also at President Trump’s side when signing a recent childhood vaccine executive order and has served as vice chair and chief policy officer at America First Policy Institute, a conservative think tank.

Regardless of her previous experience and political affiliations, this new nomination to lead the FDA has been met with both significant backlash and support toward Overton.

READ MORE: Senate Confirms Trump’s Former Surgeon General as New CDC Director

“Heidi Overton is a far-right, anti-abortion extremist who has no business leading the FDA,” wrote US Senator Patty Murray (D, Washington) on X.² “The American people deserve someone who will put science and facts FIRST, not another Trump sycophant who will make it their mission to attack medication abortion. I will vote NO.”

US Congressman and Speaker of the House Mike Johnson (R, Lousiana), however, celebrated the announcement of Overton’s new position.

“Congratulations to Dr. Heidi Overton on your well-deserved nomination to be FDA Commissioner. A woman of deep faith, an accomplished physician, and a champion for the America First agenda, Heidi has never wavered in defense of life and the values we hold dear,” he wrote on X.³ “I have seen firsthand her ability to navigate complex policy challenges with conviction and clarity. She will serve our country well.”

As her nomination heads toward a narrowly divided Senate, pharmacists and health care providers nationwide are closely monitoring how this leadership transition will affect pediatric care protocols, medication dispensing regulations, and the delicate balance of public trust in daily health decisions.^1,4

Clinical Guidance Under Fire: Upending Vaccine Protocols

For practicing pharmacists, who are central to the distribution and administration of community vaccines, the incoming commissioner's stance on immunization is of paramount importance.^4,5

Overton recently stood alongside President Trump in the Oval Office to promote an executive order aimed at reducing the number of standard childhood vaccinations from 18 diseases to 11. Specifically, the initiative seeks to split the combined measles, mumps, and rubella (MMR) vaccine into 3 separate immunizations, a move that directly opposes current medical consensus and has drawn fierce opposition from health care organizations.^1,5

Senate Health, Education, Labor, and Pensions (HELP) Committee Chair Bill Cassidy, MD, (R, Louisiana), a physician himself, expressed “strong concerns” regarding Overton's active role in the order, noting it calls into question her commitment to sound science.

Under the broader “Make America Healthy Again” movement championed by Health Secretary Robert F. Kennedy Jr., the FDA has also established additional hurdles for vaccine testing and blocked the publication of research regarding the effectiveness of COVID-19 shots.

Pharmacists may soon face the difficult task of managing inventory for separate shots while counseling parents amidst shifting federal vaccine guidance.⁵

Reproductive Health and Pharmacy Dispensing Rules

Overton’s nomination also signals a potential transformation in reproductive health regulations and drug accessibility, areas where pharmacists navigate complex legal and clinical landscapes. A vocal critic of abortion pills who celebrated the 2022 Supreme Court decision to overturn Roe v. Wade, Overton is positioned to lead an agency currently conducting a safety review of mifepristone.^1,4,5

If confirmed, she could help spearhead efforts by conservative lawmakers to reverse Biden-era rules that allow mifepristone to be mailed and dispensed via telehealth. These potential rollbacks would directly impact pharmacy logistics and compliance protocols.^1,5

Furthermore, pharmacists will need to monitor the agency's ongoing safety review of selective serotonin reuptake inhibitors.⁵

Spearheaded initially by Makary, this review investigates whether antidepressants taken during pregnancy could increase the risk of autism, cardiac birth defects, and other developmental disorders in utero, a highly sensitive clinical topic that demands precise pharmacist-led patient counseling.^5,6

Balancing Regulations with Patient Safety

The next commissioner will inherit an agency defined by a deep tension between rapid innovation and stringent evidence-based oversight. Makary's resignation followed months of internal clashes over flavored e-cigarettes and the controversial rejection of several biotech therapies for rare diseases.^4-6

Although pharmaceutical companies and patient groups often lobby for accelerated drug approvals, the pressure to ease standards introduces serious safety risks. For instance, a Kennedy-backed federal advisory panel recently recommended easing access to several popular wellness peptides, despite warnings from career FDA scientists that the chemicals have not been proven safe or effective.^4,5

As the agency grapples with these regulatory disputes, the role of the pharmacist becomes even more critical. They must serve as trusted, evidence-based gatekeepers to guide patients through a changing health care system where public confidence in federal health institutions is increasingly fragile.^1,4,5

“[Institutions responsible for public health] affect whether Americans trust vaccines; whether patients feel confident trying new treatments; whether companies continue investing in medical innovation,” concluded Forbes.⁴ “And whether the public believes the systems designed to protect them are working as intended. That is why the FDA commissioner matters—regardless of who holds the title.”

READ MORE: FDA Updates Resource Center

REFERENCES

1. Alba M, Lovelace Jr. B, Shabad R. Trump nominates Heidi Overton to lead the FDA. NBC News. August 19, 2026. Accessed August 20, 2026. https://www.nbcnews.com/politics/trump-administration/trump-heidi-overton-fda-commissioner-rcna593309

2. Murray P. Heidi Overton is a far-right, anti-abortion extremist who has no business leading the FDA. The American people deserve someone who will put science and facts FIRST, not another Trump sycophant who will make it their mission to attack medication abortion. I will vote NO. X. August 19, 2026. Accessed August 20, 2026. https://x.com/PattyMurray/status/2090114164060500181

3. Johnson M. Congratulations to Dr. Heidi Overton on your well-deserved nomination to be FDA Commissioner. A woman of deep faith, an accomplished physician, and a champion for the America First agenda, Heidi has never wavered in defense of life and the values we hold dear. I have seen firsthand her ability to navigate complex policy challenges with conviction and clarity. She will serve our country well. X. August 19, 2026. Accessed August 20, 2026. https://x.com/SpeakerJohnson/status/2090189942362083524

4. Castrucci B. How a leadership change at the FDA could impact daily lives. Forbes. May 18, 2026. Accessed August 20, 2026. https://www.forbes.com/sites/briancastrucci/2026/05/18/how-a-leadership-change-at-the-fda-could-impact-daily-lives/

5. Swenson A, Perrone M. Trump picks White House aide Dr. Heidi Overton to lead FDA. PBS News. August 19, 2026. Accessed August 20, 2026. https://www.pbs.org/newshour/politics/trump-picks-white-house-aide-dr-heidi-overton-to-lead-fda

6. Gallagher A. Makary resigns as FDA commissioner after 13 months via screenshot. Drug Topics. May 12, 2026. Accessed August 20, 2026. https://www.drugtopics.com/view/makary-resigns-as-fda-commissioner-after-13-months-via-screenshot